MANNKIND CORP Other General Expense
MANNKIND CORP (MNKD) reported Other General Expense of $2.70 million for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherGeneralExpense · last filed 2012-11-09
- MANNKIND CORP other general expense for the quarter ending 2012-09-30 was $2.70M.
- MANNKIND CORP other general expense for the quarter ending 2012-03-31 was $300.00K.
| Period end | Other General Expense 3 month |
|---|---|
| 2012-09-30 | $2.70M 10-Q · filed 2012-11-09 |
| 2012-03-31 | $300.00K 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |